# Safety and Efficacy of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation

> **NCT02913261** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 310 (actual)

## Conditions studied

- Corticosteroid Refractory Acute Graft vs Host Disease

## Interventions

- **DRUG:** Ruxolitinib (RUX)
- **DRUG:** Best Available Therapy (BAT)

## Key facts

- **NCT ID:** NCT02913261
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-10
- **Primary completion:** 2019-06-24
- **Final completion:** 2021-04-23
- **Target enrollment:** 310 (ACTUAL)
- **Last updated:** 2023-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02913261

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02913261, "Safety and Efficacy of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02913261. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*